The New England Journal of Medicine has published the results of the CORONA study. This study aimed to assess the cardiovascular benefits of rosuvastatin (Crestor®) in older patients with heart failure.
The study recruits 5,011 patients who were at least 60 years of age and had a diagnosis of heart failure (New York Heart Association class II, III or IV). Participants were randomly assigned to rosuvastatin 10mg or placebo and followed up for a median of 32.8 months. The primary outcome of the study was a composite of cardiovascular death, non-fatal myocardial infarction or non-fatal stroke.
The study found no statistical difference in the primary outcome or in the rate of all cause mortality.
Source
No comments:
Post a Comment